Adaptive Biotechnologies Corp
NASDAQ:ADPT
Adaptive Biotechnologies Corp
NASDAQ:ADPT
Price:
2.6 USD
1.96%
Market Closed
Updated:
Apr 25, 2024
P/S
Price to Sales
Price to Sales
2.2
Current
7.2
Median
3.7
Industry
Lower
than median
Lower
than industry value
Price to Sales (P/S) ratio is a valuation multiple that compares a company’s market capitalization to its revenues. It is an indicator of the value that financial markets have placed on each dollar of a company’s sales.
P/S
=2.2
Market Cap
/
377.2m
Revenue
170.3m
All Countries
| Market Cap | P/S | ||||
|---|---|---|---|---|---|
| US |
|
Adaptive Biotechnologies Corp
NASDAQ:ADPT
|
377.2m USD | 2.2 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
223.2B USD | 5.2 | |
| US |
|
Danaher Corp
NYSE:DHR
|
185.1B USD | 7.7 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
43.7B USD | 2.9 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
37.5B CHF | 5.6 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
55.5T KRW | 15 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
40.3B USD | 6 | |
| US |
|
West Pharmaceutical Services Inc
NYSE:WST
|
28.4B USD | 9.6 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26.6B USD | 7 | |
| IE |
|
ICON PLC
NASDAQ:ICLR
|
25.5B USD | 3.1 | |
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
19B EUR | 7 |
P/S Forward Multiples
Forward P/S multiple is a version of the P/S ratio that uses forecasted revenue for the P/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/S
2.1
2-Years Forward
P/S
1.7
3-Years Forward
P/S
1.3
You don't have any saved screeners yet
